NPM1 and chronic myelogenous leukemia, BCR-ABL1 positive: For CML, all of the 13 doublets that were the predicted targets of the TFs were positively co-expressed with NPM1, while for normal, three of the four doublets (75%) were negatively co-expressed with NPM1 (Fig. 4).